دورية أكاديمية
أعرض في EDS

Dynamin impacts homology-directed repair and breast cancer response to chemotherapy.

التفاصيل البيبلوغرافية
العنوان: Dynamin impacts homology-directed repair and breast cancer response to chemotherapy.
المؤلفون: Chernikova SB; Department of Radiation Oncology, Stanford University, Stanford, California, USA., Nguyen RB; Department of Radiation Oncology, Stanford University, Stanford, California, USA., Truong JT; Department of Radiation Oncology, Stanford University, Stanford, California, USA., Mello SS; Department of Radiation Oncology, Stanford University, Stanford, California, USA., Stafford JH; Department of Radiation Oncology, Stanford University, Stanford, California, USA., Hay MP; Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand., Olson A; Microscopy Service., Solow-Cordero DE; High-Throughput Bioscience Center., Wood DJ; Data Coordinating Center, Department of Biomedical Data Science, and., Henry S; Data Coordinating Center, Department of Biomedical Data Science, and., von Eyben R; Department of Radiation Oncology, Stanford University, Stanford, California, USA., Deng L; Department of Radiation Oncology, Stanford University, Stanford, California, USA., Gephart MH; Department of Neurosurgery, Stanford University, Stanford, California, USA., Aroumougame A; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Wiese C; Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado, USA., Game JC; Department of Radiation Oncology, Stanford University, Stanford, California, USA., Győrffy B; MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Budapest, Hungary.; Semmelweis University 2nd Department of Pediatrics, Budapest, Hungary., Brown JM; Department of Radiation Oncology, Stanford University, Stanford, California, USA.
المصدر: The Journal of clinical investigation [J Clin Invest] 2018 Dec 03; Vol. 128 (12), pp. 5307-5321. Date of Electronic Publication: 2018 Oct 29.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
Original Publication: New Haven [etc.] American Society for Clinical Investigation.
مواضيع طبية MeSH: Recombinational DNA Repair*, Antineoplastic Agents/*pharmacology , Dynamins/*metabolism , Triple Negative Breast Neoplasms/*drug therapy , Triple Negative Breast Neoplasms/*enzymology, Animals ; CHO Cells ; Cricetulus ; Dynamin II ; Dynamins/genetics ; Female ; Humans ; Mice ; Mice, Nude ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/pathology ; Xenograft Model Antitumor Assays
مستخلص: After the initial responsiveness of triple-negative breast cancers (TNBCs) to chemotherapy, they often recur as chemotherapy-resistant tumors, and this has been associated with upregulated homology-directed repair (HDR). Thus, inhibitors of HDR could be a useful adjunct to chemotherapy treatment of these cancers. We performed a high-throughput chemical screen for inhibitors of HDR from which we obtained a number of hits that disrupted microtubule dynamics. We postulated that high levels of the target molecules of our screen in tumors would correlate with poor chemotherapy response. We found that inhibition or knockdown of dynamin 2 (DNM2), known for its role in endocytic cell trafficking and microtubule dynamics, impaired HDR and improved response to chemotherapy of cells and of tumors in mice. In a retrospective analysis, levels of DNM2 at the time of treatment strongly predicted chemotherapy outcome for estrogen receptor-negative and especially for TNBC patients. We propose that DNM2-associated DNA repair enzyme trafficking is important for HDR efficiency and is a powerful predictor of sensitivity to breast cancer chemotherapy and an important target for therapy.
References: J Cell Biol. 2009 Jun 15;185(6):939-48. (PMID: 19528294)
J Biol Chem. 1997 Mar 21;272(12):7681-7. (PMID: 9065425)
PLoS One. 2013 Jun 25;8(6):e66243. (PMID: 23825533)
Cancer J. 2010 Jan-Feb;16(1):53-61. (PMID: 20164691)
Biochem Biophys Res Commun. 2006 Dec 22;351(3):658-63. (PMID: 17083915)
Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10394-8. (PMID: 7937961)
Dev Cell. 2006 Jun;10(6):839-50. (PMID: 16740485)
FEBS Lett. 2017 Apr;591(8):1083-1100. (PMID: 28079255)
Radiother Oncol. 2013 Jul;108(1):155-61. (PMID: 23746696)
Environ Mol Mutagen. 2010 Jul;51(6):582-603. (PMID: 20658649)
Cell. 1989 Nov 3;59(3):421-32. (PMID: 2529977)
Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1110-5. (PMID: 15650050)
Carcinogenesis. 2008 Dec;29(12):2360-8. (PMID: 18952594)
Oncogene. 2012 Mar 8;31(10):1228-41. (PMID: 21841817)
Cancer Res. 2008 Jan 1;68(1):257-65. (PMID: 18172318)
PLoS One. 2009 Aug 06;4(8):e6529. (PMID: 19657394)
Int J Cancer. 2000 Dec 15;88(6):907-13. (PMID: 11093813)
J Biol Chem. 2009 Nov 13;284(46):31945-52. (PMID: 19783859)
Proc Natl Acad Sci U S A. 1986 Sep;83(18):7034-8. (PMID: 3092225)
Ann Oncol. 2012 Aug;23 Suppl 6:vi56-65. (PMID: 23012305)
Nat Rev Cancer. 2004 Apr;4(4):253-65. (PMID: 15057285)
Gene. 1995 Oct 3;163(2):301-6. (PMID: 7590285)
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1571-6. (PMID: 25605897)
Traffic. 2013 Dec;14(12):1272-89. (PMID: 24025110)
Mol Carcinog. 2009 Feb;48(2):105-9. (PMID: 18618591)
Genes Dev. 1999 Oct 15;13(20):2633-8. (PMID: 10541549)
Breast. 2013 Dec;22(6):1178-83. (PMID: 24060578)
Cancer Chemother Pharmacol. 1998;42(4):273-9. (PMID: 9744771)
Cancer Res. 2007 Aug 1;67(15):7078-81. (PMID: 17671173)
Cell Signal. 2011 May;23(5):763-71. (PMID: 20940043)
BMC Bioinformatics. 2011 Dec 15;12:474. (PMID: 22172014)
Nat Commun. 2017 Oct 11;8(1):857. (PMID: 29021619)
Mol Cell Biol. 2004 Jul;24(13):5776-87. (PMID: 15199134)
Cancer Res. 2014 Jul 1;74(13):3546-55. (PMID: 24753542)
Biologics. 2012;6:289-97. (PMID: 22956860)
J Med Chem. 2008 Feb 14;51(3):417-23. (PMID: 18197614)
PLoS One. 2012;7(2):e30804. (PMID: 22319589)
Cancer Res. 2009 Apr 15;69(8):3589-96. (PMID: 19351835)
Radiat Res. 2001 Jun;155(6):826-31. (PMID: 11352765)
Nucleic Acids Res. 2010 Mar;38(4):1061-70. (PMID: 19942681)
BMC Cancer. 2007 Jul 24;7:134. (PMID: 17650314)
EMBO J. 2006 Jul 26;25(14):3377-88. (PMID: 16810316)
Cell Signal. 2009 Apr;21(4):529-39. (PMID: 19136058)
Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6354-8. (PMID: 7603995)
Mol Biol Cell. 1992 Oct;3(10):1181-94. (PMID: 1421574)
Mol Cell Biol. 2000 Nov;20(21):7980-90. (PMID: 11027268)
Biophys J. 2008 Jun;94(12):4957-70. (PMID: 18326650)
Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15848-53. (PMID: 18840682)
Neoplasia. 2009 Jul;11(7):683-91. (PMID: 19568413)
Cancer Res. 2007 Oct 15;67(20):9658-65. (PMID: 17942895)
Oncotarget. 2014 May 30;5(10):3261-72. (PMID: 24811120)
Philos Trans R Soc Lond B Biol Sci. 2004 Jan 29;359(1441):87-93. (PMID: 15065660)
Nat Chem Biol. 2008 Feb;4(2):119-25. (PMID: 18176557)
Biochim Biophys Acta. 2009 Dec;1796(2):266-80. (PMID: 19616605)
Mol Cancer Ther. 2006 Apr;5(4):952-61. (PMID: 16648566)
Genes Cancer. 2011 Sep;2(9):870-9. (PMID: 22593799)
J Neurol Sci. 2006 Mar 15;242(1-2):47-54. (PMID: 16386273)
Biochemistry. 1996 Aug 6;35(31):10004-13. (PMID: 8756462)
Ann Oncol. 2012 Aug;23 Suppl 6:vi46-51. (PMID: 23012302)
Bioorg Med Chem Lett. 2004 Jun 21;14(12):3275-8. (PMID: 15149689)
Cancer Biol Ther. 2012 Jan 15;13(2):61-8. (PMID: 22336907)
Breast Cancer Res Treat. 2016 Aug;159(1):41-53. (PMID: 27464795)
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34. (PMID: 17671126)
Ther Adv Med Oncol. 2012 Jul;4(4):195-210. (PMID: 22754593)
Cancer Cell. 2012 Jul 10;22(1):106-16. (PMID: 22789542)
Nat Rev Mol Cell Biol. 2011 Jul 22;12(8):517-33. (PMID: 21779028)
J Natl Cancer Inst. 2014 Jun 19;106(7):null. (PMID: 24948741)
Cancer Res. 2012 Apr 15;72(8):2111-9. (PMID: 22354749)
Breast Cancer Res Treat. 2010 Oct;123(3):725-31. (PMID: 20020197)
معلومات مُعتمدة: P01 CA067166 United States CA NCI NIH HHS; P30 NS069375 United States NS NINDS NIH HHS; R01 ES021454 United States ES NIEHS NIH HHS; UL1 RR025744 United States RR NCRR NIH HHS; R01 AG053341 United States AG NIA NIH HHS; K08 NS091527 United States NS NINDS NIH HHS; P30 CA124435 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Breast cancer; DNA repair; Oncology
المشرفين على المادة: 0 (Antineoplastic Agents)
EC 3.6.5.5 (DNM2 protein, human)
EC 3.6.5.5 (Dynamin II)
EC 3.6.5.5 (Dynamins)
تواريخ الأحداث: Date Created: 20181030 Date Completed: 20190916 Latest Revision: 20210821
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC6264728
DOI: 10.1172/JCI87191
PMID: 30371505
قاعدة البيانات: MEDLINE
الوصف
تدمد:1558-8238
DOI:10.1172/JCI87191